CMRX

Chimerix Inc

Healthcare


Presented:02/18/2022
Price:$5.62
Cap:$0.49B
Current Price:$0.85
Cap:$0.08B

Presented

Date02/18/2022
Price$5.62
Market Cap$0.49B
Ent Value$0.43B
P/E RatioN/A
Book Value$1.20
Div Yield0%
Shares O/S86.86M
Ave Daily Vol977,908
Short IntN/A

Current

Price$0.85
Market Cap$0.08B
Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded by George R. Painter, III and Timothy Wollaeger in April 2000 and is headquartered in Durham, NC.

Publicly traded companies mentioned herein: Chimerix Inc (CMRX), Siga Technologies Inc (SIGA)

Highlights

The presenter is long shares of Chimerix Inc (CMRX), a $560MM market cap biopharmaceutical company with $110MM in net cash. The company has two recently approved drugs, one treatment for smallpox and one for a rare brain cancer called diffuse midline glioma (DMG). The presenter’s thesis is that the anticipated revenues from these treatments, based on the current need, should generate the necessary earnings per share for this $5.50 stock to reach $14 in the next 18 months, offering ~150% upside.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Request access to DeMatteo Research for full access

Request Access

Already have an account?

Idea Discussion

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Idea Discussions display submitted commentary from our investor community.

To read and participate in the discussion with the presenter and investor base, request access to DeMatteo

Request Access

Already have an account?

An error occurred loading this content. Try again later or contact us.